Bezlotoxumab Reduces Rates of Recurrent C. Diff Infection Bezlotoxumab Reduces Rates of Recurrent C. Diff Infection

The monoclonal antibody bezlotoxumab reduces the rate of recurrent Clostridioides difficile infection, according to findings from the MODIFY II trial.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news